This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Selodenoson - SR
Aderis Pharmaceuticals, Inc.
Drug Names(s): DTI-0009 - SR
Description: Selodenoson is a selective adenosine A1 agonist. This mechanism is thought to reduce the rate of conduction from the heart's atria to ventricles during atrial fibrillation, without lowering blood pressure. The SR formulation is an oral one for chronic disease.
Deal Structure: A collaboration between Aderis Pharmaceuticals and Fujisawa began in June 1999 when Fujisawa licensed the US and Canadian rights to the intravenous formulation of DTI-0009. Under terms of the agreement, Fujisawa paid for clinical development and commercialization of DTI-0009, additional clinical development milestone payments, and royalty payments on sales of the product. Aderis Pharmaceuticals retained worldwide rights to oral dosage forms of DTI0009 and the rights for the DTI0009 intravenous product in markets outside North America.
In July 2004, Aderis Pharmaceuticals reacquired US & Canadian rights to the IV formulation of Selodenoson.
Additional information available to subscribers only: